Compare Incyte Corporation (INCY) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Old Dominion Freight Line Inc — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while Old Dominion Freight Line Inc trades at $233.2 (market cap $48.20B). The key difference: Old Dominion Freight Line Inc is far larger — about 2.1× Incyte Corporation's market cap, and Old Dominion Freight Line Inc pays a 0.5% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ODFL | |
|---|---|---|
Market Cap | $23.11B | $48.20B |
Sector | Health | Industrials |
52-Week High | $118.52 | $248.73 |
52-Week Low | $67.38 | $126.29 |
Enterprise Value | $19.13B | $47.95B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Old Dominion Freight Line (ODFL) trades at $231.79, down 0.88% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with an 18.46% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights improved LTL metrics and a quarterly dividend of $0.29 per share, though valuation remains elevated with a P/E of 48.82.
ODFL's outlook is supported by operational excellence and a debt-light balance sheet, but high valuation and competitive pressures from players like Amazon pose risks. Analyst consensus is mixed with a $233.67 price target, suggesting limited upside from current levels amid economic uncertainties in the freight sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
